EA201170204A1 - Антитела, нейтрализующие цитомегаловирус человека, и их применение - Google Patents
Антитела, нейтрализующие цитомегаловирус человека, и их применениеInfo
- Publication number
- EA201170204A1 EA201170204A1 EA201170204A EA201170204A EA201170204A1 EA 201170204 A1 EA201170204 A1 EA 201170204A1 EA 201170204 A EA201170204 A EA 201170204A EA 201170204 A EA201170204 A EA 201170204A EA 201170204 A1 EA201170204 A1 EA 201170204A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- human cytomegalovirus
- application
- neutralizing human
- epitope
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 4
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 101100315698 Human cytomegalovirus (strain Merlin) UL131A gene Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/002683 WO2010007463A1 (en) | 2008-07-16 | 2008-07-16 | Human cytomegalovirus neutralising antibodies and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201170204A1 true EA201170204A1 (ru) | 2011-08-30 |
Family
ID=40430130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201170204A EA201170204A1 (ru) | 2008-07-16 | 2008-07-16 | Антитела, нейтрализующие цитомегаловирус человека, и их применение |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP2960250A1 (enExample) |
| JP (1) | JP5475774B2 (enExample) |
| KR (3) | KR20140041951A (enExample) |
| CN (1) | CN102143974B (enExample) |
| AU (1) | AU2008359583B2 (enExample) |
| BR (1) | BRPI0822989A2 (enExample) |
| CA (1) | CA2730620A1 (enExample) |
| EA (1) | EA201170204A1 (enExample) |
| ES (1) | ES2548014T3 (enExample) |
| IL (1) | IL210352A0 (enExample) |
| MA (1) | MA32566B1 (enExample) |
| MX (1) | MX2011000542A (enExample) |
| NZ (1) | NZ591055A (enExample) |
| PT (1) | PT2303923E (enExample) |
| TN (1) | TN2010000616A1 (enExample) |
| WO (1) | WO2010007463A1 (enExample) |
| ZA (1) | ZA201100489B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| EP3009449B1 (en) | 2008-07-16 | 2018-06-06 | Institute for Research in Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
| PH12012501308A1 (en) | 2009-12-23 | 2013-01-21 | 4 Antibody Ag | Binding members for human cytomegalovirus |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| DK4226941T3 (da) | 2010-08-31 | 2024-12-02 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til levering af immunogen-kodende rna |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| CN102286099B (zh) * | 2011-08-05 | 2014-04-09 | 深圳市卫光生物制品股份有限公司 | 静注巨细胞病毒人免疫球蛋白及其制备方法 |
| BR112014023913B1 (pt) * | 2012-03-27 | 2022-08-09 | Variation Biotechnologies Inc | Métodos para detecção de anticorpos neutralizantes de anticitomegalovírus |
| CN116376983A (zh) | 2012-07-27 | 2023-07-04 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| WO2014099908A1 (en) * | 2012-12-17 | 2014-06-26 | Genentech, Inc. | Methods for inhibiting viral infection in transplant patients |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CN107325178A (zh) * | 2017-06-29 | 2017-11-07 | 佛山市南海区普罗圣塔生物科技有限公司 | 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用 |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US20240103009A1 (en) * | 2021-02-05 | 2024-03-28 | Amgen Inc. | Non-terminal antibody discovery methods and single cell assays |
| CN118652325B (zh) * | 2022-10-21 | 2025-05-13 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| ATE110084T1 (de) * | 1985-12-06 | 1994-09-15 | Teijin Ltd | Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung. |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1998057993A1 (en) | 1997-06-19 | 1998-12-23 | The Regents Of The University Of California | Secretory immunoglobulin produced by single cells and methods for making and using same |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| PT1781705E (pt) * | 2004-06-21 | 2014-12-23 | Medarex Llc | Anticorpos contra recetor i do interferão alfa e as suas utilizações |
| ES2546543T3 (es) * | 2005-03-14 | 2015-09-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anticuerpos monoclonales humanos contra los virus Hendra y Nipah |
| WO2007146024A2 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| GB0700133D0 (en) * | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
-
2008
- 2008-07-16 AU AU2008359583A patent/AU2008359583B2/en not_active Ceased
- 2008-07-16 JP JP2011518016A patent/JP5475774B2/ja not_active Expired - Fee Related
- 2008-07-16 KR KR1020147006967A patent/KR20140041951A/ko not_active Ceased
- 2008-07-16 WO PCT/IB2008/002683 patent/WO2010007463A1/en not_active Ceased
- 2008-07-16 CN CN200880130982.9A patent/CN102143974B/zh not_active Expired - Fee Related
- 2008-07-16 CA CA2730620A patent/CA2730620A1/en not_active Abandoned
- 2008-07-16 EP EP15172997.7A patent/EP2960250A1/en not_active Withdrawn
- 2008-07-16 EP EP08875708.3A patent/EP2303923B1/en active Active
- 2008-07-16 NZ NZ591055A patent/NZ591055A/xx not_active IP Right Cessation
- 2008-07-16 MX MX2011000542A patent/MX2011000542A/es active IP Right Grant
- 2008-07-16 KR KR20147033802A patent/KR20150002895A/ko not_active Ceased
- 2008-07-16 PT PT88757083T patent/PT2303923E/pt unknown
- 2008-07-16 ES ES08875708.3T patent/ES2548014T3/es active Active
- 2008-07-16 KR KR1020117001329A patent/KR101407216B1/ko not_active Expired - Fee Related
- 2008-07-16 BR BRPI0822989A patent/BRPI0822989A2/pt not_active IP Right Cessation
- 2008-07-16 EA EA201170204A patent/EA201170204A1/ru unknown
-
2010
- 2010-12-28 TN TNP2010000616A patent/TN2010000616A1/fr unknown
- 2010-12-29 IL IL210352A patent/IL210352A0/en unknown
-
2011
- 2011-01-19 ZA ZA2011/00489A patent/ZA201100489B/en unknown
- 2011-02-15 MA MA33620A patent/MA32566B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150002895A (ko) | 2015-01-07 |
| CN102143974B (zh) | 2015-03-25 |
| ES2548014T3 (es) | 2015-10-13 |
| BRPI0822989A2 (pt) | 2018-05-29 |
| KR20110055517A (ko) | 2011-05-25 |
| PT2303923E (pt) | 2015-08-25 |
| KR20140041951A (ko) | 2014-04-04 |
| CN102143974A (zh) | 2011-08-03 |
| MX2011000542A (es) | 2011-08-03 |
| IL210352A0 (en) | 2011-03-31 |
| AU2008359583A1 (en) | 2010-01-21 |
| KR101407216B1 (ko) | 2014-06-16 |
| AU2008359583B2 (en) | 2012-04-05 |
| EP2303923A1 (en) | 2011-04-06 |
| ZA201100489B (en) | 2013-03-27 |
| CA2730620A1 (en) | 2010-01-21 |
| EP2303923B1 (en) | 2015-06-24 |
| JP5475774B2 (ja) | 2014-04-16 |
| EP2960250A1 (en) | 2015-12-30 |
| TN2010000616A1 (en) | 2012-05-24 |
| MA32566B1 (fr) | 2011-08-01 |
| NZ591055A (en) | 2012-08-31 |
| WO2010007463A1 (en) | 2010-01-21 |
| JP2011527899A (ja) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201170204A1 (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| EA201170205A1 (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| EA201270571A1 (ru) | Человеческие il-23-антигенсвязывающие белки | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| MY150709A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| EA201290589A1 (ru) | Cd127-связывающие белки | |
| EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
| EA201492149A8 (ru) | St2-антигенсвязывающие белки | |
| EA201170357A1 (ru) | Инженерные антитела к il-13: композиции, способы и применение | |
| EA201291039A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
| EA201001335A1 (ru) | Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение | |
| EA201201116A1 (ru) | Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а | |
| EA201790330A1 (ru) | Белки, связывающиеся с bcma (cd269/tnfrsf17) | |
| EA201291243A1 (ru) | Антитела против респираторно-синцитиального вируса (рсв) и способы их применения | |
| EA200800812A1 (ru) | Композиции антитела против cd3 | |
| EA201300256A1 (ru) | Антитела к рецептору эпидермального фактора роста-3 (her3) | |
| EA032929B1 (ru) | Нейтрализующее вирус иммунодефицита человека антитело и способы его применения | |
| EA201270662A1 (ru) | Связывающие элементы для человеческого цитамегаловируса | |
| EA201300239A1 (ru) | Антитела к fap и способы их применения | |
| EA200970874A1 (ru) | Антитела против склеростина | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| EA201171237A1 (ru) | Антитела к dkk-1 | |
| NO20090069L (no) | Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse | |
| EA201491724A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
| WO2011092593A3 (en) | Hiv-1 neutralizing antibodies and uses thereof |